Diffusion-weighted magnetic resonance imaging as an alternative to positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in patients with lymphomas: a literature review and clinical observations
https://doi.org/10.17650/1818-8346-2025-20-1-65-72
Abstract
Diffusion‑weighted magnetic resonance imaging may provide an alternative to traditional methods such as computed tomography and positron emission tomography / computed tomography with 18F‑fluorodeoxyglucose. The article analyzes not only the advantages of the method, but also the disadvantages and pitfalls that a diagnostician has to face. data from own studies on the use of whole‑body diffusion‑weighted magnetic resonance imaging in patients with lymphomas are presented.
Keywords
diffusion‑weighted magnetic resonance imaging,
computed tomography,
fluorodeoxyglucose,
non‑Hodgkin’s lymphoma,
positron emission tomography,
measured diffusion coefficient
Supporting agencies: The work was performed without external funding
About the Authors
S. A. Alekseev
Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
Sergey Anatolievich Alekseev
105094; 3 Gospital’naya Ploshchad’; Moscow
V. N. Troyan
Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
105094; 3 Gospital’naya Ploshchad’; Moscow
O. A. Rukavitsyn
Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
105094; 3 Gospital’naya Ploshchad’; Moscow
A. A. Trefilov
Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
105094; 3 Gospital’naya Ploshchad’; Moscow
References
1. Rukavitsyn O.A., Troyan V.N., Kryukov E.V. et al. Radiologic diagnostics for blood system diseases. Moscow: GEOTARMedia, 2021. 224 p. (In Russ.). DOI: 10.33029/970463338DIA20211224
2. Rukavitsyn O.A., Udal’eva V.Yu., Ageeva T.A. et al. Hematology : National Guide. 2<sup>nd</sup> edn, revised and supplemented. Moscow: GEOTAR-Media, 2024. 916 p. (In Russ.). DOI: 10.33029/970481882GEM20241916
3. Glockner J.F., Hu H.H., Stanley D.W. et al. Parallel MR imaging: a user’s guide. Radiographics 2005;25(5):1279–97. DOI: 10.1148/rg.255045202
4. Ballon D., Watts R., Dyke J.P. et al. Imaging therapeutic response in human bone marrow using rapid wholebody MRI. Magn Reson Med 2004;52(6):1234–8. DOI: 10.1002/mrm.20291
5. De Bazelaire C., de Kerviler E. From multislice CT to wholebody biomarker imaging in lymphoma patients. Eur Radiol 2011;21(3):555–8. DOI: 10.1007/s0033001020359
6. Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31(11):1860–1.
7. Cheson B.D. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4(1):5. DOI: 10.3978/j.issn.23043865.2014.11.03
8. Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and nonHodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–68. DOI: 10.1200/JCO.2013.54.8800
9. Brenner D., Elliston C., Hall E. et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176(2):289–96. DOI: 10.2214/ajr.176.2.1760289
10. Mathews J.D., Forsythe A.V., Brady Z. et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013;346:f2360. DOI: 10.1136/bmj.f2360
11. Jerusalem G., Beguin Y., Najjar F. et al. Positron emission tomography (PET) with <sup>18</sup>Ffluorodeoxyglucose (18FFDG) for the staging of lowgrade nonHodgkin’s lymphoma (NHL). Ann Oncol 2001;12(6):825–30. DOI: 10.1023/a:1011169332265
12. Townsend D.W. Multimodality imaging of structure and function. Phys Med Biol 2008;53(4):R1–39. DOI: 10.1088/00319155/53/4/R01
13. Kwee T.C., Takahara T., Ochiai R. et al. Wholebody diffusion-weighted magnetic resonance imaging. Eur J Radiol 2009;70(3):409–17. DOI: 10.1016/j.ejrad.2009.03.054
14. Darge K., Jaramillo D., Siegel M.J. Wholebody MRI in children: current status and future applications. Eur J Radiol 2008;68(2): 289–98. DOI: 10.1016/j.ejrad.2008.05.018
15. Wong F.C., Kim E.E. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009;70(2):205–11. DOI: 10.1016/j.ejrad.2009.01.049
16. Lin C., Luciani A., Itti E. et al. Wholebody diffusionweighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large Bcell lymphoma. Eur Radiol 2010;20(8):2027–38. DOI: 10.1007/s003300101758y
17. Dudeck O., Zeile M., Pink D. et al. Diffusionweighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with softtissue sarcomas. J Magn Reson Imaging 2008;27(5):1109–13. DOI: 10.1002/jmri.21358
18. Wu X., KellokumpuLehtinen P.L., Pertovaara H. et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large Bcell lymphoma – a pilot study: comparison with 2-deoxy2-fluoro-Dglucosepositron emission tomography/computed tomography. NMR Biomed 2011;24(10):1181–90. DOI: 10.1002/nbm.1689
19. Chen Y., Zhong J., Wu H., Chen N. The clinical application of wholebody diffusionweighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 2012;30(2):165–70. DOI: 10.1016/j.mri.2011.09.019
20. Gu J., Chan T., Zhang J. et al. Wholebody diffusionweighted imaging: the added value to wholebody MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197(3):W384–91. DOI: 10.2214/AJR.10.5692
21. Stéphane V., Samuel B., Vincent D. et al. Comparison of PETCT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82(11):2011–7. DOI: 10.1016/j.ejrad.2013.05.042
22. Van Ufford H.M., Kwee T.C., Beek F.J. et al. Newly diagnosed lymphoma: initial results with wholebody T1-weighted, STIR, and diffusionweighted MRI compared with 18FFDG PET/CT. AJR Am J Roentgenol 2011;196(3):662–9. DOI: 10.2214/AJR.10.4743
23. Padhani A.R., Koh D.M., Collins D.J. Wholebody diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700–18. DOI: 10.1148/radiol.11110474
24. Le Bihan D., Poupon C., Amadon A., Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 2006;24(3):478–88. DOI: 10.1002/jmri.20683
25. Nasu K., Kuroki Y., Sekiguchi R. et al. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006;24(6):438–44. DOI: 10.1007/s116040060053y
26. Koh D.M., Padhani A.R. Diffusionweighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006;79(944):633–5. DOI: 10.1259/bjr/29739265
27. Connors J.M. Stateoftheart therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23(26):6400–8. DOI: 10.1200/JCO.2005.05.016
28. Eissa L., Abdel Razek A.A.K., Helmy E. Arterial spin labeling and diffusionweighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63–8. DOI: 10.1016/j.clinimag.2020.10.057
29. Eraky A.M., Beck R.T., Treffy R.W. et al. Role of advanced MR imaging in diagnosis of neurological malignancies: current status and future perspective. J Integr Neurosci 2023;22(3):73. DOI: 10.31083/j.jin2203073
30. Giraudo C., Simeone R., Fosio M. et al. Diagnostic value of PET/MR with DWI for Burkitt lymphoma. Diagnostics (Basel) 2021;11(10):1867. DOI: 10.3390/diagnostics11101867
31. Hwang S., Panicek D.M. Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol 2007;36(11):1017–27. DOI: 10.1007/s0025600703084
32. Liu Y., Wang Y., Wang P., Yu Q. A retrospective study to evaluate the CT and MR imaging findings of nonHodgkin’s lymphoma affecting the jaw bones. Oral Radiol 2022;38(4):509–16. DOI: 10.1007/s1128202100582y
33. Sharma S., Leung W.H., Deqing P. et al. Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging. Bone Marrow Transplant 2012;47(8):1067–74. DOI: 10.1038/bmt.2011.234
34. Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI: 10.3322/caac.21763
35. Thuy T.T.M., Trang N.T.H., Vy T.T. et al. Role of diffusionweighted MRI in differentiation between benign and malignant anterior mediastinal masses. Front Oncol 2022;12:985735. DOI: 10.3389/fonc.2022.985735
36. ToledanoMassiah S., Luciani A., Itti E. et al. Wholebody diffusionweighted imaging in Hodgkin lymphoma and diffuse large Bcell lymphoma. Radiographics 2015;35(3):747–64. DOI: 10.1148/rg.2015140145
37. Winzer R., Hoberück S., Zöphel K. et al. Diffusion-weighted MRI for initial staging in Hodgkin’s lymphoma: comparison with FDG PET. Eur J Radiol 2020;123:108775. DOI: 10.1016/j.ejrad.2019.108775
Review
For citations:
Alekseev S.A., Troyan V.N., Rukavitsyn O.A., Trefilov A.A. Diffusion-weighted magnetic resonance imaging as an alternative to positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in patients with lymphomas: a literature review and clinical observations. Oncohematology. 2025;20(1):65-72. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-1-65-72
Views:
162
Email this article 